Chevy Chase Trust’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-5,005
Closed -$368K 641
2022
Q1
$368K Sell
5,005
-60
-1% -$5.35K ﹤0.01% 609
2021
Q4
$725K Sell
5,065
-115
-2% -$19.8K ﹤0.01% 593
2021
Q3
$1.07M Buy
5,180
+75
+1% +$16.5K ﹤0.01% 575
2021
Q2
$1.08M Hold
5,105
﹤0.01% 573
2021
Q1
$926K Buy
+5,105
New +$1.02M ﹤0.01% 575
2019
Q2
Sell
-500
Closed -$5K 654
2019
Q1
$5K Hold
500
﹤0.01% 656
2018
Q4
$18K Hold
500
﹤0.01% 708
2018
Q3
$19K Hold
500
﹤0.01% 661
2018
Q2
$13K Hold
500
﹤0.01% 679
2018
Q1
$21K Hold
500
﹤0.01% 662
2017
Q4
$12K Hold
500
﹤0.01% 676
2017
Q3
$11K Sell
500
-350
-41% -$7.84K ﹤0.01% 673
2017
Q2
$20K Hold
850
﹤0.01% 655
2017
Q1
$22K Hold
850
﹤0.01% 650
2016
Q4
$21K Hold
850
﹤0.01% 658
2016
Q3
$35K Hold
850
﹤0.01% 647
2016
Q2
$124K Hold
850
﹤0.01% 632
2016
Q1
$88K Hold
850
﹤0.01% 641
2015
Q4
$143K Hold
850
﹤0.01% 648
2015
Q3
$120K Hold
850
﹤0.01% 647
2015
Q2
$189K Hold
850
﹤0.01% 654
2015
Q1
$141K Hold
850
﹤0.01% 658
2014
Q4
$101K Hold
850
﹤0.01% 681
2014
Q3
$71K Buy
850
+350
+70% +$31.6K ﹤0.01% 688
2014
Q2
$46K Hold
500
﹤0.01% 683
2014
Q1
$45K Hold
500
﹤0.01% 657
2013
Q4
$51K Buy
+500
New +$35.3K ﹤0.01% 645

Other funds holding NVAX

Chevy Chase Trust's NVAX Position: Q2 2022 in Review

Chevy Chase Trust sold out of Novavax (NVAX) in Q2 2022, closing a stake of 5,005 shares — an estimated $368K sold.

Chevy Chase Trust first reported a position in NVAX in Q4 2013 and held it in 27 quarters. The position peaked at $1.08M in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

  • Chevy Chase Trust reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
  • Chevy Chase Trust sold 5,005 Novavax shares in Q2 2022, an estimated $368K.
  • Chevy Chase Trust first reported a position in Novavax in Q4 2013 and held it in 27 quarters.
  • Chevy Chase Trust's Novavax position peaked at $1.08M in Q2 2021.
  • 325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Chevy Chase Trust's 13F filing for Q2 2022, filed 10 Aug 2022.